Navigation Links
Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
Date:2/11/2010

or the long-term clinical efficacy and safety of velaglucerase alfa," said Pramod Mistry, MD, PhD, FRCP, Professor of Pediatrics & Internal Medicine at Yale University School of Medicine. "The Gaucher community is very fortunate to have velaglucerase alfa as an option for patients."

Results from Study TKT032 in Adults and Children

TKT032 was a 12-month, randomized, double-blind, parallel-group global study in 25 treatment-naive patients aged two years and older that evaluated velaglucerase alfa at 45 U/kg and velaglucerase alfa at 60 U/kg. Patients were eligible to participate in the study if they presented with disease-related anemia and had at least one of the following clinical manifestations of Gaucher disease: thrombocytopenia, moderate splenomegaly or a readily palpable enlarged liver.

The primary endpoint was change in hemoglobin concentrations from baseline at 60 U/kg. Secondary endpoints for both doses were changes in platelet counts, changes in organ volumes, changes in surrogate markers of Gaucher disease, and for the 45 U/kg dose only, change in hemoglobin concentrations from baseline.

At 12 months, in the 60 U/kg group, statistically significant changes in mean hemoglobin concentration increased 23.3%, +2.43+/-0.32 g/dL, P< 0.0001; mean platelet count increased 65.9%, +50.9+/-12.2x10(9)/L, P=0.0016; and mean spleen volume decreased 50%, -1.92+/-0.51% body weight, P=0.0032, from 14.0 multiples of normal [MN] at baseline to 5.75 MN. Mean liver volume decreased 17%, -0.84+/-0.33% body weight, P=0.0282, from 1.46 to 1.22 MN.

Results for 45 U/kg were consistent with those observed with 60 U/kg; however a dose-related effect in favor of velaglucerase alfa at 60 U/kg was observed by platelet count increase and liver volume reduction between the 2 dose groups.

Adverse events
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
2. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
3. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
4. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
5. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
6. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
7. Shire Continues to Deliver Excellent Growth From Core Products
8. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
9. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
10. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
11. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 3, 2015 Today, the ... Internet. As markets become ever more transparent, the importance ... AG recognised long ago. Its maxim of "innovation brings ... networking and digitisation. The company has long ... "state of the art" technology and modern approach, while ...
(Date:6/2/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... of products for the treatment of central nervous system ... M.D., Vanda,s President and CEO, will deliver a corporate ... New York City on Thursday, June ... The presentation at the Jefferies Global Healthcare Conference will ...
(Date:6/2/2015)... N.C. , June 2, 2015 Kewaunee ... Board of Directors declared a quarterly cash dividend of ... 2015 to stockholders of record at the close of ... Kewaunee Scientific Founded in 1906, Kewaunee Scientific ... manufacture, and installation of laboratory, healthcare, and technical furniture ...
Breaking Medicine Technology:
... Sweden, September 1 Calabar AB, a privately,held ... announced a EUR 350,000 equity financing from the ... Calabar,s product,through a phase II study with repeated ... drug on the minor glands will lead to ...
... 1 Biosensors,International Group, Ltd ("Biosensors", "Company"), ... drug-eluting stent,developed by Biosensors, has demonstrated equal ... Johnson,s industry leading drug-eluting stent, CYPHER,SELECT(TM) ("Cypher"), ... The results of the landmark study were ...
Cached Medicine Technology:Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 2Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 3
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 ... system was released to public yesterday, and has ... Internet. HonestyFirstReviews.com's senior product reviewer Tiffany Hendricks has ... detailed review of the course on her website ... courses available for Internet marketers looking to hone ...
(Date:6/2/2015)... 02, 2015 On March 19th, 2015, ... in the Hall of Legends at Detroit’s Ford Field. ... speaker Herman Moore, the goal of the conference was ... today’s society, highlight the benefits of effective professional rehabilitation ... about the options that are available to them in ...
(Date:6/2/2015)... The Down Syndrome Association of Wisconsin ... hit show Glee as the keynote speaker for its ... Prairie, WI. The event aims to raise funds to ... and Walworth counties. , "We couldn't ... this important event," says Dawn Nuoffer, DSAW Executive Director. ...
(Date:6/2/2015)... The Horizon Blue Cross Blue Shield of ... and Wellness Challenge, held this past weekend during the ... $3,000 for the Boys & Girls Club of Atlantic ... steps on her fitbit during her play at the ... in Galloway Township. , When added to Horizon ...
(Date:6/2/2015)... June 02, 2015 “ Radaris ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... data they need on a person. , According to Psychology ... even goes on to explain that curiosity is a part ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2
... 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a ... reported improvements in his patients, but he died shortly ... was never conducted. Now, a group of neurological ... work in a study to see if Charcot,s observation ...
... the more than 36 million people plagued by tinnitus, ... worsening the functional and emotional toll of chronic ringing, ... according to a new study from Henry Ford Hospital ... between insomnia and the severity of perceived tinnitus symptoms, ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, April ... Wednesday issued the first national standards to curb air pollution ... to hydraulic fracturing, a way to obtain natural gas by ... release gas. Natural gas is being touted by ...
... two years later, Sarah Clark grimaces sheepishly and insists she ... "I was woefully unprepared," says Clark, a researcher ... Skyline High School in Ann Arbor. "I did not do ... math homework that night. I sent him to school the ...
... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
... Lisa Esposito HealthDay Reporter , WEDNESDAY, April 18 ... a specific number of fights and years in the ring ... head without brain damage, a new study suggests. But, ... show. "The brain can tolerate or absorb a ...
Cached Medicine News:Health News:19th century therapy for Parkinson's disease may help patients today 2Health News:Study: Insomnia takes toll on tinnitus patients 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 3Health News:Football helmet sensors help researchers demystify concussion in young athletes 2Health News:Speed and ecstasy associated with depression in teenagers 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 3
Designed to lift corneal cap/flap during corneal lamellar surgery...
... Refractive drape has two perforations ... adapts to various single or ... draping. Refractive drape has two ... Drape adapts to various single ...
Unique 2 in 1 design allows simultaneous absorption of excess fluid & protection of flap & hinge, Lint-free PVAmaterial....
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: